Hims & Hers Health's (HIMS) "Sell" Rating Reaffirmed at Citigroup

Citigroup reiterated their sell rating on shares of Hims & Hers Health (NYSE:HIMS - Free Report) in a research report report published on Thursday morning,Benzinga reports. Citigroup currently has a $27.00 target price on the stock.

HIMS has been the topic of several other research reports. Bank of America lifted their price target on shares of Hims & Hers Health from $18.00 to $21.00 and gave the company an "underperform" rating in a research report on Thursday, February 20th. TD Cowen reaffirmed a "buy" rating and set a $28.00 price target on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Canaccord Genuity Group lifted their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research report on Wednesday, February 19th. Leerink Partners lifted their price target on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research report on Tuesday, February 25th. Finally, Morgan Stanley lowered shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and lifted their price target for the company from $42.00 to $60.00 in a research report on Tuesday, February 18th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $37.23.

Remove Ads

Hims & Hers Health Price Performance

HIMS stock traded up $1.62 during trading on Thursday, hitting $36.01. The stock had a trading volume of 23,509,501 shares, compared to its average volume of 13,182,499. Hims & Hers Health has a twelve month low of $11.20 and a twelve month high of $72.98. The stock has a market capitalization of $8.00 billion, a P/E ratio of 81.85 and a beta of 1.37. The company's 50-day moving average price is $37.64 and its two-hundred day moving average price is $27.60.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $481.14 million for the quarter, compared to analysts' expectations of $494.56 million. As a group, sell-side analysts expect that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Soleil Boughton sold 4,152 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total value of $251,984.88. Following the completion of the sale, the insider now directly owns 157,345 shares of the company's stock, valued at approximately $9,549,268.05. This represents a 2.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Michael Chi sold 7,259 shares of the stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $24.07, for a total transaction of $174,724.13. Following the transaction, the insider now directly owns 193,601 shares of the company's stock, valued at $4,659,976.07. This represents a 3.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,062,011 shares of company stock worth $36,892,724. Corporate insiders own 17.71% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Crewe Advisors LLC purchased a new position in Hims & Hers Health during the fourth quarter worth about $28,000. Raleigh Capital Management Inc. increased its holdings in Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after buying an additional 1,100 shares in the last quarter. Blume Capital Management Inc. increased its holdings in Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after buying an additional 600 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after buying an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC purchased a new position in Hims & Hers Health in the fourth quarter valued at about $38,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.